Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / APLS - Apellis Pharmaceuticals: Empaveli Approved With A Broad Label

APLS - Apellis Pharmaceuticals: Empaveli Approved With A Broad Label

Apellis Pharmaceuticals Inc.
  • Apellis announced the FDA approval of Empaveli for the treatment of PNH patients.
  • Empaveli's label includes all adults with PNH which was a positive surprise.
  • Empaveli was priced at $458,000 per patient per year, the same price as Ultomiris and a discount to Soliris.
  • Empaveli has a strong value proposition for patients poorly controlled by C5 inhibitors.

For further details see:

Apellis Pharmaceuticals: Empaveli Approved With A Broad Label
Stock Information
Company Name: Apellis Pharmaceuticals Inc.
Stock Symbol: APLS
Market: NASDAQ
Website: apellis.com
Menu
APLS APLS Quote APLS Short APLS News APLS Articles APLS Message Board
Get APLS Alerts

News, Short Squeeze, Breakout and More Instantly...